Category Post

LEQEMBI® IQLIK™ Autoinjector Named One of TIME’s Best Inventions of 2025

LEQEMBI® IQLIK™ Named One of TIME’s Best Inventions of 2025 for Transforming Alzheimer’s Treatment Access Eisai Co., Ltd. and Biogen Inc. today announced that LEQEMBI® IQLIK™ (lecanemab-irmb), the first subcutaneous autoinjector formulation of the Alzheimer’s disease therapy lecanemab, has been…

Read MoreLEQEMBI® IQLIK™ Autoinjector Named One of TIME’s Best Inventions of 2025

Final Fintepla® OLE Study Results in Lennox-Gastaut Syndrome Published in Epilepsy & Behavior

UCB Publishes Final Analysis of Fintepla® Open-Label Extension Study in Lennox-Gastaut Syndrome Demonstrating Sustained Seizure Reduction and Improved Quality of Life UCB, a global biopharmaceutical company, announced that the final analysis of its open-label extension (OLE) study evaluating Fintepla® (fenfluramine)…

Read MoreFinal Fintepla® OLE Study Results in Lennox-Gastaut Syndrome Published in Epilepsy & Behavior